IGF1R and Miyoshi myopathy: Although IGF1R is supposed to be an important oncogene in MM and other malignant diseases [30,31,32] and promising findings were made in vitro [33,34,35,36], significant clinical responses to monotherapies with IGF1R inhibitors have not been achieved in patients [37,38].